MedPAC Reviews 2027 Medicare Physician Payment Update and Site-Neutral Policies

MedPAC proposes a 0.5% increase to Medicare physician payments in 2027 amid access and reimbursement debates, highlighting site-neutral payment considerations for hospital outpatient settings.

CMS Launches ACCESS Model to Advance Technology-Supported Chronic Care

CMS introduces the ACCESS Model to improve Medicare chronic care with digital health innovation and outcome-based payments starting 2026.

CMS Launches ACCESS Model to Advance Outcome-Based Payments in Medicare FFS

CMS initiates the ACCESS Model, a 10-year voluntary program testing outcome-based payments for Medicare fee-for-service providers, enhancing integrated, tech-supported chronic care.

CMS Final Home Health Medicare Rule Cuts Payments by 1.3%, Revises Methodology

CMS's finalized Medicare payment rule for home health agencies reduces payments by 1.3% and revises payment methodology following industry feedback, signaling modest future increases but immediate financial challenges.

New York Mandates Insurer Coverage for Lung Cancer Follow-Up Screenings

Starting 2027, New York insurers must cover lung cancer follow-up screening and diagnostics without member cost sharing, following clinical guidelines and allowing insurer medical management.

Hospital Margins Stabilize Amid Rising Volumes and Site-Neutral Payment Challenges

September 2025 data shows stabilizing hospital margins with increasing patient volumes. Site-neutral payment policies and AI-driven documentation shifts impact reimbursement and operations.

Tyson Plant Closure and Medicare Choices Impact Nebraska's Insurance Landscape

Explore how Tyson's Lexington plant closure and Medicare choices are reshaping insurance and risk considerations in Nebraska's agriculture and healthcare sectors.

CMS Announces 9.7% Medicare Part B Premium Increase for 2026

CMS announces a 9.7% increase in Medicare Part B premiums for 2026, affecting individuals earning $109,000 or less. Updates on oncology drug reimbursement and legal challenges to the CMS 340B drug rebate pilot program highlight shifting dynamics in Medicare regulation and healthcare compliance.

CMS Negotiates Discounts on 15 Drugs, Including Cancer Therapies

CMS has secured significant price reductions on 15 drugs including costly cancer treatments, impacting Medicare Part B pricing and healthcare costs.

Medicare-X Choice Act Reintroduced to Expand Affordable Public Insurance Option

U.S. Senators reintroduce Medicare-X Choice Act to create a public health insurance option aimed at expanding coverage, reducing costs, and increasing competition within ACA and Medicare frameworks.